The Datar tests come from Datar Cancer Genetics, a laboratory company based in Nashik, India, with laboratories serving the United Kingdom, Germany and the United States. Its tests are built on circulating tumor cells, living cancer cells in the blood, and especially on tiny clusters of tumor-associated cells that the company reports are found in people with cancer and rarely in people without it. Datar offers blood tests for cancer screening, blood tests for people with a suspicious growth, and a comprehensive tumor analysis that includes testing live cancer cells against chemotherapy and natural substances. This article explains each test, what the published studies show, and how Datar compares with the other blood-test laboratories.
Cancer Expert MD has no financial relationship with Datar Cancer Genetics or any other laboratory and receives nothing for referrals.
How the Datar Approach Works
Tumors release cells into the bloodstream, singly and in small clusters. Datar’s laboratories isolate these cells from a blood sample, identify them by their surface markers, and study them. The company’s central finding, published in the International Journal of Cancer in 2020, is that clusters of tumor-associated cells were common in more than 5,500 people with cancer and were found in under 4 percent of more than 10,600 people without symptoms.1 Some Datar tests also examine tumor DNA in the blood at the same time. Our article on circulating tumor cell testing explains the science behind these cells.
The Main Datar Tests
Trucheck is a screening blood test for people without symptoms. The company reports that it was validated in more than 57,000 people and detected cancer with a sensitivity of 88 percent across stages and types, and that an extended version can suggest which of up to 70 types of solid tumor is present.
Trublood is for people who already have a suspicious growth in the breast, lung, prostate, colon or brain. It looks for tumor cell clusters to help judge whether the growth is likely cancer, and is aimed at cases where a biopsy is risky or not possible. It carries the CE mark for use in Europe.
Exacta is a comprehensive analysis of a fresh tumor biopsy or of tumor cells from the blood. It combines DNA and RNA testing with functional testing of live cancer cells against chemotherapy drugs and natural substances, similar in concept to the RGCC test from Greece.
TriNetra-Breast is a breast cancer screening blood test being evaluated in a pivotal study of about 700 women aged 40 and older in the United States.2
What the Published Studies Show
The RESILIENT trial. In this trial at a cancer center in Nashik, published in Oncotarget in 2019, people whose advanced cancers had progressed after at least two lines of treatment received drug combinations chosen by Datar’s comprehensive tumor analysis, which included testing their live cancer cells against drugs. Of the 126 patients evaluated, 54 had their tumors shrink substantially, a response rate of 42.9 percent, and the cancer was controlled in 90.5 percent at the end of the study. Follow-up was short, a median of about four and a half months.3
Testing from blood alone. Because several patients in RESILIENT could not safely have a new biopsy, the company followed with a pilot trial, LIQUID IMPACT, that chose treatment from blood-based analysis instead.
What is still missing. Most published Datar studies were run or sponsored by the company, and RESILIENT had no comparison group. For screening, the key question for any multi-cancer test is whether finding cancer earlier this way leads to fewer cancer deaths, which has not yet been shown for any such test, and a positive result in someone without cancer leads to further scans and worry. Our article on multi-cancer early detection blood tests explains what the major 2026 studies of screening tests showed.
Datar, RGCC and Maintrac Compared
All three laboratories work with circulating tumor cells, but they emphasize different questions. Datar focuses most on detecting cancer, in screening and in people with a suspicious growth, and on comprehensive analysis to guide treatment. RGCC in Greece focuses on counting the cells and testing them against chemotherapy and about 50 natural substances. Maintrac in Germany focuses on counting cells repeatedly to track whether treatment is working. Our article on cancer testing in Germany and Greece covers RGCC and Maintrac in more detail.
Practical Points
Ordering. The tests are ordered through a physician or practitioner who works with the laboratory, and blood is drawn locally and shipped.
Cost. The tests are generally not covered by insurance in the United States, so confirm the price before ordering.
Consistency. Different laboratories use different methods, so results from one cannot be compared with results from another. Follow-up tests should stay with the same laboratory.
Whether a Datar test adds useful information depends on the question being asked: screening, an unclear growth, or choosing treatment for advanced cancer. In a consultation, Dr. Silver, MD, educates you on Datar and the other advanced tests, what each can and cannot show, and how the results fit together.
How Cancer Expert MD Helps
Cancer Expert MD provides education and consultation for people with every type and stage of cancer, and specializes in Stage IV and metastatic cancer. Our book, The New Reality of Cancer, describes the testing available in each country in detail and how to combine blood tests, sequencing and imaging into one plan. See also our advanced cancer testing guide.
Frequently Asked Questions
What is the Datar test?
A family of blood and tumor tests from Datar Cancer Genetics that detect and analyze circulating tumor cells and clusters, used for screening, for evaluating a suspicious growth, and for guiding treatment.
What is Trucheck?
Datar’s screening blood test for people without symptoms, which looks for circulating tumor cells and clusters released by cancers.
How accurate are the Datar tests?
The company reports high accuracy in its own studies. Independent studies and trials showing that screening with these tests reduces cancer deaths are not yet available.
What is the difference between Datar and RGCC?
Both work with circulating tumor cells. Datar focuses more on detecting cancer and on comprehensive tumor analysis, while RGCC focuses on counting the cells and testing them against chemotherapy and natural substances.
About the author. Dr. Silver, MD, graduated from Temple University School of Medicine, completed fellowship training in cardiology, and has practiced medicine for nearly fifty years. A lymphoma survivor of about twenty-five years, he is co-author, with Dr. Lindmeier, DHSc, of The New Reality of Cancer: The Science of Recovery. Read more about Dr. Silver, MD.
Research by Dr. Lindmeier, DHSc, cancer educator and co-author of The New Reality of Cancer.
This article is for general education only and is not individual medical advice. Always consult your own doctor before making any changes to your care.
© 2026 Lovely LYF LLC. All rights reserved. This article draws on the research in The New Reality of Cancer and may not be copied, republished or distributed without written permission.
For more in-depth information on this topic and many others, get our book, The New Reality of Cancer: The Science of Recovery.
Explore our guides: Stage 4 Cancer Options · Advanced Cancer Testing · Integrative Cancer Treatment Options · Natural Compounds and Cancer · Repurposed Drugs for Cancer · Cancer Treatment by Type
More articles on advanced cancer testing and all articles.
References
- Circulating ensembles of tumor-associated cells: a redoubtable new systemic hallmark of cancer. International Journal of Cancer. 2020.
- An evaluation of a circulating tumor cell-based test (TriNetra-Breast) for breast cancer screening in women aged 40 and above. ClinicalTrials.gov NCT06043661.
- Nagarkar R, Patil D, Crook T, et al. Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial. Oncotarget. 2019;10(54):5605–5621.
This article is for education only. It is not medical advice and does not diagnose or treat any condition. Cancer Expert MD has no financial relationship with any laboratory, drug maker, supplement company, clinic or hospital.
Leave a Reply